Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

First-in-class mRNA-based therapeutic cancer vaccine

Cel

Immunotherapy is revolutionising cancer treatment, providing advantages over traditional chemotherapy. Instead of injection of toxic chemical compounds, immunotherapy activates body's native defences to kill abnormal tissues, such as cancer cells. In addition, activated immune system offers long term protection against recurrence of cancer.

However, current immunotherapies – Immune Checkpoint Inhibitors and CAR T – have reached critical limitations: the incredible effects are only achieved in select cases and further innovation is only incremental. Thus, to make immunotherapy universal, a qualitative leap is required.

mRNA as a therapeutic has the potential to create the next level cancer immunotherapy, serious challenges remain. mRNA needs a delivery system that helps it reach the interior of the specific immune cells, but the current-state-of-the-art delivery technology is LNP (lipid nanoparticles), accumulates mRNA off-target into liver, where it has no impact on neither immune system activation nor tumours.

Vectiopep has developed a precision drug delivery method that enables selective transport of mRNA into the patients' immune cells in spleen. The proprietary delivery technology relies on natural, biodegradable peptides, offering an advantage over artificial lipids. By combining the precision delivery with the capacity of a single mRNA to encode multiple antigens, Vectiopep can simultaneously educate and activate powerful killer immune cells for a robust, multi-pronged attack on cancer.

Vectiopep has demonstrated in several aggressive animal tumour models that the technology treats cancer, is effective even at low doses, and has long-lasting effects. Thus, the technology has the potential to bring about the required qualitative leap in cancer immunotherapy.

Dziedzina nauki (EuroSciVoc)

Słowa kluczowe

Program(-y)

Temat(-y)

System finansowania

HORIZON-CSA - HORIZON Coordination and Support Actions

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) HORIZON-WIDERA-2025-02

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

vectiopep OU
Wkład UE netto
€ 499 695,00
Adres
Tartu maakond, Kambja vald, Haaviku tee 16
61702 Kulitse alevik
Estonia
MŚP
Tak
Region
Eesti Eesti Lõuna-Eesti
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
Brak danych